AB2 Bio operates as a drug discovery and development company that specializes in developing therapies for the treatment of severe systemic inflammatory diseases. The Company primarily focuses on developing drugs that treat the symptoms, as well as target the underlying causes of inflammation-based diseases. Its portfolio includes Interleukin-18 Binding Protein, a human protein with a high affinity for IL-18, a major inflammatory cytokine for inflammatory diseases treatment.